Search
Contineum Therapeutics Inc
CTNMAdd to Watchlist
15.100USD
-0.140-0.92%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
563.53MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of Contineum Therapeutics Inc is 8.86, ranking 43 out of 387 in the Biotechnology & Medical Research industry. The average price target is 22.00, with a high of 29.00 and a low of 14.00.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
22.333
Target Price
+46.54%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Contineum Therapeutics Inc
CTNM
7
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Contineum Therapeutics Inc's price target?
Analysts forecast that Contineum Therapeutics Inc's price target is USD 22.00, with the highest forecast at USD 29.00 and the lowest forecast at USD 14.00.
How have Contineum Therapeutics IncCTNM's recent earnings per share performed?
The market expectation was USD -0.39, while Contineum Therapeutics IncCTNM's earnings per share (EPS) for the previous quarter was USD -0.49. EPS for the next quarter is expected at USD -0.48.
What is the analyst rating for Contineum Therapeutics Inc?
Based on the ratings of Contineum Therapeutics Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.